Brokerages Set Ascendis Pharma A/S (NASDAQ:ASND) PT at $173.88

Ascendis Pharma A/S (NASDAQ:ASND) has been assigned a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $173.88.

Several research firms have recently weighed in on ASND. Wells Fargo & Company raised their price objective on shares of Ascendis Pharma A/S from $260.00 to $262.00 and gave the company an “overweight” rating in a research report on Friday. Citigroup raised their price objective on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a “buy” rating in a research report on Thursday, February 8th. Wedbush raised their price objective on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an “outperform” rating in a research report on Thursday, February 8th. Morgan Stanley reissued an “equal weight” rating and issued a $116.00 target price on shares of Ascendis Pharma A/S in a research report on Monday, April 22nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $173.00 target price on shares of Ascendis Pharma A/S in a research report on Friday.

Ascendis Pharma A/S Stock Down 2.3 %

Shares of ASND opened at $134.00 on Friday. The firm has a 50-day moving average price of $146.20 and a 200 day moving average price of $128.38. The firm has a market capitalization of $7.80 billion, a PE ratio of -13.94 and a beta of 0.54. Ascendis Pharma A/S has a 52-week low of $83.75 and a 52-week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.15) by $0.49. The firm had revenue of $148.62 million during the quarter, compared to analyst estimates of $97.02 million. Ascendis Pharma A/S had a negative net margin of 152.68% and a negative return on equity of 16,574.15%. On average, equities analysts expect that Ascendis Pharma A/S will post -4.15 EPS for the current year.

Institutional Trading of Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently modified their holdings of ASND. Vestal Point Capital LP acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter valued at about $78,719,000. Massachusetts Financial Services Co. MA boosted its position in shares of Ascendis Pharma A/S by 20.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,519,219 shares of the biotechnology company’s stock valued at $191,346,000 after acquiring an additional 254,749 shares in the last quarter. Westfield Capital Management Co. LP increased its stake in Ascendis Pharma A/S by 6.0% in the fourth quarter. Westfield Capital Management Co. LP now owns 4,030,634 shares of the biotechnology company’s stock valued at $507,658,000 after acquiring an additional 228,457 shares during the period. First Turn Management LLC acquired a new position in Ascendis Pharma A/S in the fourth quarter worth about $19,092,000. Finally, abrdn plc bought a new position in Ascendis Pharma A/S during the fourth quarter worth about $17,481,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.